These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Triple therapy for neovascular age-related macular degeneration (verteporfin photodynamic therapy, intravitreal dexamethasone, and intravitreal bevacizumab). Ehmann D; García R Can J Ophthalmol; 2010 Feb; 45(1):36-40. PubMed ID: 20130708 [TBL] [Abstract][Full Text] [Related]
23. Efficacy of intravitreal bevacizumab (Avastin) therapy for early and advanced neovascular age-related macular degeneration. Krebs I; Lie S; Stolba U; Zeiler F; Felke S; Binder S Acta Ophthalmol; 2009 Sep; 87(6):611-7. PubMed ID: 18937801 [TBL] [Abstract][Full Text] [Related]
24. Efficacy of intravitreal bevacizumab combined with photodynamic therapy for polypoidal choroidal vasculopathy. Gomi F; Sawa M; Wakabayashi T; Sasamoto Y; Suzuki M; Tsujikawa M Am J Ophthalmol; 2010 Jul; 150(1):48-54.e1. PubMed ID: 20609707 [TBL] [Abstract][Full Text] [Related]
26. Intravitreal bevacizumab (Avastin) treatment of neovascular age-related macular degeneration. Emerson MV; Lauer AK; Flaxel CJ; Wilson DJ; Francis PJ; Stout JT; Emerson GG; Schlesinger TK; Nolte SK; Klein ML Retina; 2007; 27(4):439-44. PubMed ID: 17420695 [TBL] [Abstract][Full Text] [Related]
27. Intravitreal bevacizumab for treatment of neovascular age-related macular degeneration: the second year of a prospective study. Bashshur ZF; Haddad ZA; Schakal AR; Jaafar RF; Saad A; Noureddin BN Am J Ophthalmol; 2009 Jul; 148(1):59-65.e1. PubMed ID: 19375689 [TBL] [Abstract][Full Text] [Related]
28. A prospective study on different methods for the treatment of choroidal neovascularization. The efficacy of verteporfin photodynamic therapy, intravitreal bevacizumab and transpupillary thermotherapy in patients with neovascular age-related macular degeneration. Nowak MS; Jurowski P; Grzybowski A; Goś R; Pastuszka M; Kapica A; Śmigielski J Med Sci Monit; 2012 Jun; 18(6):CR374-80. PubMed ID: 22648253 [TBL] [Abstract][Full Text] [Related]
29. Intravitreal bevacizumab for the management of choroidal neovascularization in age-related macular degeneration. Bashshur ZF; Bazarbachi A; Schakal A; Haddad ZA; El Haibi CP; Noureddin BN Am J Ophthalmol; 2006 Jul; 142(1):1-9. PubMed ID: 16815245 [TBL] [Abstract][Full Text] [Related]
31. Single-session photodynamic therapy combined with intravitreal bevacizumab for neovascular age-related macular degeneration. Ahmadieh H; Taei R; Soheilian M; Riazi-Esfahani M; Ahadi H Eur J Ophthalmol; 2008; 18(2):297-300. PubMed ID: 18320527 [TBL] [Abstract][Full Text] [Related]
32. Short-term safety and efficacy of intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Rich RM; Rosenfeld PJ; Puliafito CA; Dubovy SR; Davis JL; Flynn HW; Gonzalez S; Feuer WJ; Lin RC; Lalwani GA; Nguyen JK; Kumar G Retina; 2006; 26(5):495-511. PubMed ID: 16770255 [TBL] [Abstract][Full Text] [Related]
33. Effect of photodynamic therapy alone or combined with posterior subtenon triamcinolone acetonide or intravitreal bevacizumab on choroidal hypofluorescence by indocyanine green angiography. Hatta Y; Ishikawa K; Nishihara H; Ozawa S; Ito Y; Terasaki H Retina; 2010 Mar; 30(3):495-502. PubMed ID: 19996828 [TBL] [Abstract][Full Text] [Related]
34. Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration in treatment-naive patients. Pedersen KB; Sjølie AK; Møller F Acta Ophthalmol; 2009 Nov; 87(7):714-9. PubMed ID: 19094171 [TBL] [Abstract][Full Text] [Related]
40. Prospective study of intravitreal triamcinolone acetonide versus bevacizumab for macular edema secondary to central retinal vein occlusion. Ding X; Li J; Hu X; Yu S; Pan J; Tang S Retina; 2011 May; 31(5):838-45. PubMed ID: 21293319 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]